MONDAY, Oct. 7, 2024 — For patients with relapsed/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen receptor T-cell product, lisocabtagene maraleucel (liso-cel), is safe for outpatients and inpatients…Original Article
Liso-Cel Has Favorable Safety Profile for Outpatients With Large B-Cell Lymphoma
MONDAY, Oct. 7, 2024 — For patients with relapsed/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen receptor T-cell product, lisocabtagene maraleucel (liso-cel), is safe for outpatients and inpatients…
